Search results
Showing 8866 to 8880 of 8904 results
25 years of NICE and focusing on what matters most to deliver for the future
Home News Podcasts 25 years of NICE and focusing on what matters most to deliver for the future Podcasts 01 May 2024 Listen About this episode
Home News Podcasts Assessing the familial and genetic risk of ovarian cancer Podcasts 03 April 2024 Listen About this episode We talk to Ranjit
Learn more about the NICE and NHS England MedTech Pathway consultation
Home News Podcasts Learn more about the NICE and NHS England MedTech Pathway consultation Podcasts 03 June 2024 Listen About this episode
Learn more about NICE's new guideline on identifying and managing adrenal insufficiency
Home News Podcasts Learn more about NICE's new guideline on identifying and managing adrenal insufficiency Podcasts 29 August 2024 Listen
170,000 people in England to have further treatment choice for preventing migraine attacks
In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.
New life-extending drug treatment for children and teenagers with an aggressive form of brain cancer
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients..
New functionality for online collaboration on consultations, enables groups or organisations to submit a joined-up response.
Avelumab not recommended as a maintenance treatment of urothelial cancer
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.
Learn more about the proposed changes to our routing criteria for highly specialised technologies
Home News Podcasts Learn more about the proposed changes to our routing criteria for highly specialised technologies Podcasts 31 December 2024
Additional evidence needed to assess histology-independent cancer drugs
A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.
NICE and NIHR: working together to produce research with impact
Alice and Zoe discuss how the National Institute of Health Research (NIHR) and NICE work in partnership and identify key research priorities from NICE guidance.
Dr Roberts, who is a qualified doctor, has 20 years’ experience in clinical and management posts in healthcare both in the private and public sector.
Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
Patient safety and surgical innovation – why new isn't always better
Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.
Children and young people set to benefit from new treatment for peanut allergy
Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.